Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
2.
Biochemistry (Mosc) ; 67(1): 65-74, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11841341

ABSTRACT

Blood coagulation plays a key role among numerous mediating systems that are activated in inflammation. Receptors of the PAR family serve as sensors of serine proteinases of the blood clotting system in the target cells involved in inflammation. Activation of PAR-1 by thrombin and of PAR-2 by factor Xa leads to a rapid expression and exposure on the membrane of endothelial cells of both adhesive proteins that mediate an acute inflammatory reaction and of the tissue factor that initiates the blood coagulation cascade. Certain other receptors (EPR-1, thrombomodulin, etc.), which can modulate responses of the cells activated by proteinases through PAR receptors, are also involved in the association of coagulation and inflammation together with the receptors of the PAR family. The presence of PAR receptors on mast cells is responsible for their reactivity to thrombin and factor Xa and defines their contribution to the association of inflammation and blood clotting processes.


Subject(s)
Blood Coagulation , Inflammation , Receptors, Thrombin/metabolism , Animals , Humans , Models, Biological , Platelet Membrane Glycoproteins/metabolism , Protein Binding , Receptor, PAR-1 , Receptor, PAR-2 , Receptors, Cell Surface/metabolism , Thrombin/metabolism
3.
Vopr Med Khim ; 48(6): 570-6, 2002.
Article in Russian | MEDLINE | ID: mdl-12698556

ABSTRACT

Polymer dressings with encapsulated thrombin or synthetic peptides which can mimic thrombin action are employed for wound healing. Paper describes the method for preparation of these hydrogel composites of PVCL-CaAlg [poly(N-vinyl caprolactam-calcium alginate). The effect of encapsulated thrombin/peptides on tissue repair process have beet investigatat in vivo experiments using a mouse model of wound healing. The developed dressings accelerated wound healing: thascan be used as a basis for creation of novel formulations with controlled drug release for wound therapy.


Subject(s)
Caprolactam/analogs & derivatives , Peptide Fragments/chemistry , Thrombin/chemistry , Wound Healing/drug effects , Alginates/chemistry , Animals , Caprolactam/chemistry , Drug Carriers , Enzymes, Immobilized , Glucuronic Acid , Hexuronic Acids , Hydrogels , Mice , Mice, Inbred CBA , Peptide Fragments/therapeutic use , Polymers/chemistry , Receptor, PAR-1 , Receptor, PAR-2 , Receptors, Thrombin/agonists , Thrombin/therapeutic use
4.
Clin Appl Thromb Hemost ; 7(4): 325-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11697718

ABSTRACT

To accelerate the healing processes in wound repair, attempts have been repeatedly made to use growth factors including thrombin and its peptide fragments. Unfortunately, the employment of thrombin is limited because of its high liability and pro-inflammatory actions at high concentrations. Some cellular effects of thrombin in wound healing are mediated by the activation of protease activated receptor-1 (PAR-1). The thrombin receptor agonist peptide (TRAP:SFLLRN) activates this receptor and mimics the effects of thrombin, but TRAP is a relatively weak agonist. We speculated that the encapsulated peptide may be more effective for PAR-1 activation than nonimmobilized peptide and developed a novel method for TRAP encapsulation in hydrogel films based on natural and synthetic polymers. The effects of an encapsulated TRAP in composite poly(N-vinyl caprolactam)-calcium alginate (PVCL) hydrogel films were investigated in a mouse model of wound healing. On day 7 the wound sizes decreased by about 60% under TRAP-chitosan-containing PVCL films, as compared with control films without TRAP. In the case of TRAP-polylysine-containing films no significant decrease in wound sizes was found. The fibroblast/macrophage ratio increased under TRAP-containing films on day 3 and on day 7. The number of proliferating fibroblasts increased to 150% under TRAP-chitosan films on day 7 as compared with control films. The number of [3H]-thymidine labeled endothelial and epithelial cells in granulation tissues was also enhanced. Thus, the immobilized TRAP to PVCL-chitosan hydrogel films were found to promote wound healing following the stimulation of fibroblast and epithelial cell proliferation and neovascularization. Furthermore, TRAP was shown to inhibit the secretion of the inflammatory mediator PAF from stimulated rat peritoneal mast cells due to augmentation of NO release from the mast cells. The encapsulated TRAP is suggested to accelerate wound healing due to the anti-inflammatory effects and earlier development of the proliferative phase of wound healing.


Subject(s)
Drug Delivery Systems/methods , Proteins/pharmacology , Wound Healing/drug effects , Adjuvants, Immunologic/pharmacology , Animals , Drug Compounding , Mast Cells/drug effects , Mast Cells/immunology , Mast Cells/metabolism , Methylgalactosides , Mice , Models, Animal , Nitric Oxide/metabolism , Receptors, Thrombin/agonists
6.
Biochemistry (Mosc) ; 64(6): 658-64, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10395981

ABSTRACT

The effect of a thrombin receptor agonist peptide (TRAP-6) on the release of nitric oxide (NO) and platelet activating factor (PAF) from resting and calcium-ionophore (A23187)-activated rat peritoneal mast cells (RPMC) was studied using a platelet aggregation bioassay. RPMC spontaneously released NO, which inhibited TRAP-6-, ADP-, and PAF-stimulated platelet aggregation. This effect of NO was abolished by the addition of an NO binding agent, oxyhemoglobin (oxyHb), to the platelet suspension. The RPMC-induced suppression of platelet aggregation was completely inhibited by the NO-synthase inhibitor L-NAME. TRAP-6 and its high affinity analog haTRAP stimulated the rapid release of NO from RPMC. The effect of TRAP-6 was inhibited by pretreatment of the RPMC with L-NAME or with the inhibitor of the constitutive NO-synthase isoform (cNOS) calmidazolium. TRAP-6 inhibited PAF release from A23187-activated RPMC via an NO-dependent mechanism. Platelet aggregation induced by PAF release from activated RPMC was also confirmed in experiments using the PAF receptor antagonist ginkgolide B. Thus, TRAP-6 is a rapidly acting modulator of mast cell reactivity; it stimulates NO release and inhibits PAF secretion.


Subject(s)
Mast Cells/drug effects , Nitric Oxide/physiology , Receptors, Thrombin/agonists , Animals , Calcimycin/pharmacology , Inflammation , Peptide Fragments/pharmacology , Peritoneum/metabolism , Platelet Activating Factor/metabolism , Rats , Thrombin/physiology
7.
Bioorg Khim ; 24(4): 288-92, 1998 Apr.
Article in Russian | MEDLINE | ID: mdl-9612571

ABSTRACT

Thrombin, binding to receptors of the protease activated receptor (PAR) family, is involved in wound healing by inducing the reparation processes and regulating the activity of mast cells, which secrete mediators of inflammation. Using thrombin receptor agonist peptide (TRAP-6) for the activation of rat mast cells, effect of several receptors, including PAR-1, on mast cells was demonstrated. It was shown that TRAP increases the concentration of Ca2+ in the cytoplasm of mast cells and regulates cell degranulation, while releasing nitrogen oxide. Thrombin encapsulated in poly(N-vinyl caprolactam)-calcium alginate (PVCL-Ca-Alg) hydrogel films promotes wound healing in rats as demonstrated by the acceleration of fibroblast proliferation and neovascularization.


Subject(s)
Peptide Fragments/pharmacology , Receptors, Thrombin/agonists , Thrombin/physiology , Wound Healing/physiology , Animals , Calcium/metabolism , Caprolactam/analogs & derivatives , Caprolactam/chemistry , Cell Degranulation/drug effects , Cytoplasm/drug effects , Cytoplasm/metabolism , Drug Compounding , Mast Cells/drug effects , Mast Cells/metabolism , Neovascularization, Physiologic/drug effects , Nitric Oxide/metabolism , Polymers/chemistry , Rats , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...